Hanlin (02696.HK) announced that the new application for supplemental indications for HLX01 products, HL (rituximab injection), was approved by the State Drug Administration. The company says it is expected to further expand the product indications and provide more options for domestic follicular lymphoma and chronic lymphocytic leukemia patients. (gc/a) ~
ASDAK Financial News
Website: www.aastocks.com